Retrospective analysis to validate the CTS5 in patients from <i>El Álamo IV</i> registry and GEICAM adjuvant studies

The CTS5 categorized patients based on late DR risk regardless of menopausal status, ET duration, or CT treatment. However, the model tended to overestimate events, particularly in high-risk groups, especially among those treated with ET for less than 60 months or not receiving CT.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2025-04-01
DOI
https://doi.org/10.1093/oncolo/oyaf040
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

Purificación Martínez del Prado, I. Álvarez, Sònia Servitja, Begoña Bermejo et al.
The Oncologist
Breast Cancer Treatment Studies
article

Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

Purificación Martínez del Prado, I. Álvarez, Sònia Servitja, Begoña Bermejo, Marina Pollán, Lourdes Calvo, Jesús Herránz, Eva Carrasco, Óscar Polonio, Sara López‐Tarruella, Encarna Adrover, Manuel Ruíz-Borrego, Álvaro Rodríguez-Lescure, Montserrat Muñoz-Mateu, Antonio Antón, Miguel Martín, Raquel Andrés, María Marín, Ángel Guerrero-Zotano, L. Fernández, Diana Moreno
article en

Abstract

The CTS5 categorized patients based on late DR risk regardless of menopausal status, ET duration, or CT treatment. However, the model tended to overestimate events, particularly in high-risk groups, especially among those treated with ET for less than 60 months or not receiving CT.

The OncologistVol. 30(4)
Universidad de Zaragoza (ES), Instituto de Salud Carlos III (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital de Basurto (ES), Hospital Clínico Universitario de Valencia (ES), Consorci Sanitari de Terrassa (ES), Biogipuzkoa Health Research Institute (ES), Hospital Universitario Fundación Alcorcón (ES), Fundación Instituto Valenciano de Oncología (ES), Centro Nacional de Epidemiología (ES), Hospital Universitario Miguel Servet (ES), Hospital Clínic de Barcelona (ES), Corporació Sanitària Parc Taulí (ES), Hospital General Universitario de Elche (ES), Hospital Del Mar (ES), Hospital Clínico Universitario Lozano Blesa (ES), Instituto de Investigación Sanitaria Aragón (ES), Biomedical Research Institute (US), Complexo Hospitalario Universitario A Coruña (ES), Hospital General Universitario de Albacete (ES), Hospital Universitario Virgen del Rocío (ES), INCLIVA Health Research Institute (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), GEICAM – Spanish Breast Cancer Group (ES)
Good health and well-being
Openalex Percentile: Top 92%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.